Status: Recruiting
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
Participants needed: 37
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: May 12, 2026Locations: 7
Eligibility criteria
Willing and able to provide written informed consent for the trial. [+24]
Recurrent rectal cancer. [+14]